Frankfurt - Delayed Quote EUR

FibroGen, Inc. (1FG.F)

Compare
0.3715
-0.0008
(-0.21%)
At close: 8:08:28 AM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Thane Wettig CEO & Director 907.67k -- 1965
Mr. David DeLucia Chief Financial Officer -- -- --
Mr. Michael D. Lowenstein J.D., Ph.D. Chief Legal Officer -- -- --
Mr. Julian N. Stern Secretary 26.15k -- 1925

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200 https://www.fibrogen.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
486

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Corporate Governance

FibroGen, Inc.’s ISS Governance QualityScore as of March 1, 2025 is 6. The pillar scores are Audit: 9; Board: 1; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 5, 2025 at 10:59 AM UTC - May 9, 2025 at 12:00 PM UTC

FibroGen, Inc. Earnings Date

Recent Events

Related Tickers

NB11.F Vaxart, Inc.
0.4818
-1.79%
 
MBIO.CN MindBio Therapeutics Corp.
0.0200
+33.33%
 
ARTL Artelo Biosciences, Inc.
1.0000
-6.54%
 
ATXS Astria Therapeutics, Inc.
6.10
-5.28%
 
SCPX Scorpius Holdings, Inc.
0.1599
-6.49%
 
CTMX CytomX Therapeutics, Inc.
0.6503
-3.97%
 
ALLR Allarity Therapeutics, Inc.
0.8801
+10.19%
 
NKTR Nektar Therapeutics
0.8019
-4.54%
 
RENB Renovaro Inc.
0.8937
-9.05%
 
CDT Conduit Pharmaceuticals Inc.
1.1600
-3.33%